עינייםבעריכת ד"ר איתי חונה

Xalacom (latanoprost/timolol) More Effective than Cosopt

FORT LAUDERDALE, FL — May 8, 2002 —

Xalacom® (fixed combination latanoprost 0.005% and timolol 0.5%) once-daily is more effective for the reduction of intraocular pressure (IOP) than Cosopt (fixed combination dorzolamide 2% and timolol 0.5%) twice-daily in patients with open-angle glaucoma or ocular hypertension, according to a study presented at the annual conference of the Association for Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, FL.

The study – conducted by RM Feldman, M.D., University of Texas Health and Science

Center, Houston, TX and DH Shin, M.D., Kresge Eye Institute, Wayne State University, Detroit, MI – compared the efficacy and safety of Xalacom and Cosopt over three months in patients whose IOP was inadequately controlled on monotherapy.

 “This study’s findings underscore the importance of Xalacom in the arsenal of IOP lowering medications,” said Dr. Feldman. “Fixed combination therapies may be key to improving compliance among patients who do not respond to monotherapy, and in this study Xalacom was more effective than Cosopt.”

 The study – conducted at 30 eye centers in the United States on 251 patients with primary open angle glaucoma or ocular hypertension – was a randomized, parallel group, masked-evaluator, multicenter comparison of Xalacom and Cosopt. After three months of treatment, mean diurnal (± standard error of the mean) IOP reduction from baseline was 9.4 ± 0.27 mmHg for Xalacom and 8.4 ± 0.26 mmHg for Cosopt. Xalacom recorded a mean difference in IOP reduction of 1.00 mmHg versus Cosopt. The difference was statistically significant
(p<0.005).

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר